Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data

Autor: Akiko Tsubota, Masahiko Nakayama, Stephane Cheung, Yukinobu Hamuro, Jörg Mahlich
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Oncology
Male
medicine.medical_treatment
Cancer Treatment
lcsh:Medicine
Antiandrogen
urologic and male genital diseases
Biochemistry
Medical Records
Geographical Locations
Gonadotropin-Releasing Hormone
Prostate cancer
0302 clinical medicine
Mathematical and Statistical Techniques
Japan
Medicine and Health Sciences
030212 general & internal medicine
Young adult
lcsh:Science
Routes of Administration
Principal Component Analysis
Multidisciplinary
Pharmaceutics
Prostate Cancer
Prostate Diseases
Hormonal Therapy
Middle Aged
Prostatic Neoplasms
Castration-Resistant
Treatment Outcome
030220 oncology & carcinogenesis
Physical Sciences
Androgens
Hormonal therapy
Statistics (Mathematics)
Research Article
Adult
medicine.medical_specialty
Asia
Adolescent
Antineoplastic Agents
Hormonal
medicine.drug_class
Urology
Research and Analysis Methods
03 medical and health sciences
Young Adult
Pharmacotherapy
Drug Therapy
Internal medicine
medicine
Humans
Statistical Methods
Aged
Neoplasm Staging
Retrospective Studies
Pharmacology
Chemotherapy
business.industry
lcsh:R
Cancer
Cancers and Neoplasms
Biology and Life Sciences
Prostatic Neoplasms
Retrospective cohort study
Androgen Antagonists
medicine.disease
Hormones
Genitourinary Tract Tumors
People and Places
Multivariate Analysis
lcsh:Q
business
Mathematics
Zdroj: PLoS ONE, Vol 13, Iss 4, p e0195789 (2018)
PLoS ONE
ISSN: 1932-6203
Popis: Background Limited availability of real-world data that describe treatment patterns of Japanese prostate cancer (PCA) patients. Methods A biweekly transition analysis of PCA treatment was performed for patients with PCA diagnosis and a specific treatment between 2010 and 2015. To account for different cancer stages, two patient populations were analyzed. The first group consisted of patients on medication for hormone-sensitive prostate cancer (HSPC). The second group is comprised of patients who ended up receiving specific therapy for castration-resistant prostate cancer (CRPC). For each treatment, the average of treatment duration and the portion of patients transitioning to a consecutive treatment was calculated. Results We identified 59,626 patients from the Japanese administrative database with a PCA diagnosis and specific treatment. In the first year of our observational study 786 patients commenced a HSPC treatment and 695 received a CRPC specific therapy Among the HSPC group, we found that combination hormonal therapy, comprised of a gonadotrophin releasing hormone agonist or antagonist with an antiandrogen was more common than monotherapy. The results of the CRPC group indicated that chemotherapy administration was for a shorter time period in a real-world setting as compared to published clinical studies. Conclusion Utilizing a novel method to visualize real-world treatment pathways for PCA patients we found that real treatment pathways are in line with international guidelines.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje